A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Respimat(®) Soft Mist(™) Inhaler (SMI) is a hand-held device that generates an aerosol with a high, fine-particle fraction, enabling efficient lung deposition. The study objective was to assess inhalation success among children using Respimat SMI, and the requirement for assistance by the parent/caregiver and/or a valved holding chamber (VHC).
Methods: This open-label study enrolled patients aged <5 years with respiratory disease and history of coughing and/or recurrent wheezing. Patients inhaled from the Respimat SMI (air only; no aerosol) using a stepwise configuration: "1" (dose released by child); "2" (dose released by parent/caregiver), and "3" (Respimat SMI with VHC, facemask, and parent/caregiver help). Co-primary endpoints included the ability to perform successful inhalation as assessed by the investigators using a standardized handling questionnaire and evaluation of the reasons for success. Inhalation profile in the successful handling configuration was verified with a pneumotachograph. Patient satisfaction and preferences were investigated in a questionnaire.
Results: Of the children aged 4 to <5 years (n=27) and 3 to <4 years (n=30), 55.6% and 30.0%, respectively, achieved success without a VHC or help; with assistance, another 29.6% and 10.0%, respectively, achieved success, and the remaining children were successful with VHC. All children aged 2 to <3 years (n=20) achieved success with the Respimat SMI and VHC. Of those aged <2 years (n=22), 95.5% had successful handling of the Respimat SMI with VHC and parent/caregiver help. Inhalation flow profiles generally confirmed the outcome of the handling assessment by the investigators. Most parent/caregiver and/or child respondents were satisfied with operation, instructions for use, handling, and ease of holding the Respimat SMI with or without a VHC.
Conclusions: The Respimat SMI is suitable for children aged <5 years; however, children aged <5 years are advised to add a VHC to complement its use.
Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management.
Saxena D, Murugesan N, Evbayiro U, Ngassa M, Adrish M J Pers Med. 2024; 14(8).
PMID: 39202058 PMC: 11355058. DOI: 10.3390/jpm14080867.
Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma.
Santamaria F, Ziello C, Lorello P, Bouche C, Borrelli M Front Pediatr. 2022; 10:896865.
PMID: 35928684 PMC: 9343620. DOI: 10.3389/fped.2022.896865.
Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients.
Zielen S, Reichert G, Donath H, Trischler J, Schulze J, Eickmeier O J Asthma Allergy. 2021; 14:23-30.
PMID: 33469318 PMC: 7813466. DOI: 10.2147/JAA.S274544.
The Respimat Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients.
Iwanaga T, Tohda Y, Nakamura S, Suga Y Clin Drug Investig. 2019; 39(11):1021-1030.
PMID: 31377981 PMC: 6800401. DOI: 10.1007/s40261-019-00835-z.
Asthma Across Age: Insights From Primary Care.
Kaplan A, Hardjojo A, Yu S, Price D Front Pediatr. 2019; 7:162.
PMID: 31131265 PMC: 6510260. DOI: 10.3389/fped.2019.00162.